Morgan Stanley lowered the firm’s price target on Fractyl Health (GUTS) to $8 from $10 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health Appoints New Chief Financial Officer
- Fractyl Health appoints Lara Smith Weber as CFO
- Fractyl Health: Advancing Revita and Rejuva Pipelines Toward 2026 Clinical and Regulatory Catalysts Supports Buy Rating
- Fractyl Health Announces Catalyst-Rich Clinical and Funding Outlook
- Fractyl Health outlines strategic outlook for 2026